Which has better valuation and earnings, EXEL or RLAY?

Exelixis has higher revenue and earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exelixis $2.50B 6.91 $782.57M $3.34 21.17 Relay Therapeutics $10.35M 421.00 -$276.48M -$1.51 N/A

Does the media favor EXEL or RLAY?

In the previous week, Relay Therapeutics had 5 more articles in the media than Exelixis. MarketBeat recorded 19 mentions for Relay Therapeutics and 14 mentions for Exelixis. Relay Therapeutics' average media sentiment score of 0.74 beat Exelixis' score of 0.67 indicating that Relay Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 5 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive Relay Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ASND or RLAY?

In the previous week, Relay Therapeutics had 10 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 19 mentions for Relay Therapeutics and 9 mentions for Ascendis Pharma A/S. Relay Therapeutics' average media sentiment score of 0.74 beat Ascendis Pharma A/S's score of 0.54 indicating that Relay Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Relay Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to HALO or RLAY?

In the previous week, Halozyme Therapeutics had 15 more articles in the media than Relay Therapeutics. MarketBeat recorded 34 mentions for Halozyme Therapeutics and 19 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 0.74 beat Halozyme Therapeutics' score of 0.40 indicating that Relay Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Halozyme Therapeutics 7 Very Positive mention(s) 6 Positive mention(s) 14 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Relay Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to BBIO or RLAY?

In the previous week, Relay Therapeutics had 10 more articles in the media than BridgeBio Pharma. MarketBeat recorded 19 mentions for Relay Therapeutics and 9 mentions for BridgeBio Pharma. BridgeBio Pharma's average media sentiment score of 0.87 beat Relay Therapeutics' score of 0.74 indicating that BridgeBio Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Relay Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is RLAY or SMMT more profitable?

Relay Therapeutics' return on equity of -40.25% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Relay Therapeutics N/A -40.25% -36.82% Summit Therapeutics N/A -138.82% -117.11%

Does the media refer more to RLAY or SMMT?

In the previous week, Relay Therapeutics had 2 more articles in the media than Summit Therapeutics. MarketBeat recorded 19 mentions for Relay Therapeutics and 17 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 0.94 beat Relay Therapeutics' score of 0.74 indicating that Summit Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relay Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Summit Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Relay Therapeutics (RLAY) Competitors

$19.72 -0.22 (-1.10%)

Closing price 11/11/2026 04:00 PM Eastern

Extended Trading

$19.45 -0.27 (-1.37%)

As of 04:54 AM Eastern

Compare

RLAY vs. EXEL, ASND, HALO, BBIO, and SMMT

Should you buy Relay Therapeutics stock or one of its competitors? Relay Therapeutics's main competitors and comparable companies include Exelixis (EXEL), Ascendis Pharma A/S (ASND), Halozyme Therapeutics (HALO), BridgeBio Pharma (BBIO), and Summit Therapeutics (SMMT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Relay Therapeutics compare to Exelixis?

Exelixis (NASDAQ:EXEL) and Relay Therapeutics (NASDAQ:RLAY) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation.

Exelixis has a net margin of 35.45% compared to Relay Therapeutics' net margin of 0.00%. Exelixis' return on equity of 45.54% beat Relay Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.45%	45.54%	33.90%
Relay Therapeutics	N/A	-40.25%	-36.82%

Exelixis has higher revenue and earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.50B	6.91	$782.57M	$3.34	21.17
Relay Therapeutics	$10.35M	421.00	-$276.48M	-$1.51	N/A

85.3% of Exelixis shares are held by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are held by institutional investors. 2.6% of Exelixis shares are held by company insiders. Comparatively, 5.0% of Relay Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Relay Therapeutics had 5 more articles in the media than Exelixis. MarketBeat recorded 19 mentions for Relay Therapeutics and 14 mentions for Exelixis. Relay Therapeutics' average media sentiment score of 0.74 beat Exelixis' score of 0.67 indicating that Relay Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	5 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive
Relay Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Exelixis currently has a consensus price target of $58.85, indicating a potential downside of 16.77%. Relay Therapeutics has a consensus price target of $27.00, indicating a potential upside of 36.92%. Given Relay Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Relay Therapeutics is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	1 Sell rating(s)	10 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.39
Relay Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

Exelixis has a beta of 0.45, meaning that its share price is 55% less volatile than the broader market. Comparatively, Relay Therapeutics has a beta of 1.74, meaning that its share price is 74% more volatile than the broader market.

Summary

Relay Therapeutics beats Exelixis on 9 of the 16 factors compared between the two stocks.

How does Relay Therapeutics compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and Relay Therapeutics (NASDAQ:RLAY) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

Ascendis Pharma A/S has a net margin of 70.99% compared to Relay Therapeutics' net margin of 0.00%. Ascendis Pharma A/S's return on equity of 32.54% beat Relay Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	70.99%	32.54%	7.71%
Relay Therapeutics	N/A	-40.25%	-36.82%

Ascendis Pharma A/S currently has a consensus target price of $305.95, indicating a potential upside of 18.00%. Relay Therapeutics has a consensus target price of $27.00, indicating a potential upside of 36.92%. Given Relay Therapeutics' higher probable upside, analysts clearly believe Relay Therapeutics is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0 Sell rating(s)	2 Hold rating(s)	19 Buy rating(s)	0 Strong Buy rating(s)	2.90
Relay Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

97.0% of Relay Therapeutics shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by insiders. Comparatively, 5.0% of Relay Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Relay Therapeutics had 10 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 19 mentions for Relay Therapeutics and 9 mentions for Ascendis Pharma A/S. Relay Therapeutics' average media sentiment score of 0.74 beat Ascendis Pharma A/S's score of 0.54 indicating that Relay Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Relay Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ascendis Pharma A/S has higher revenue and earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	19.86	-$258M	$12.89	20.11
Relay Therapeutics	$10.35M	421.00	-$276.48M	-$1.51	N/A

Ascendis Pharma A/S has a beta of 0.4, indicating that its stock price is 60% less volatile than the broader market. Comparatively, Relay Therapeutics has a beta of 1.74, indicating that its stock price is 74% more volatile than the broader market.

Summary

Ascendis Pharma A/S beats Relay Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Relay Therapeutics compare to Halozyme Therapeutics?

Halozyme Therapeutics (NASDAQ:HALO) and Relay Therapeutics (NASDAQ:RLAY) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends.

Halozyme Therapeutics has a net margin of 26.93% compared to Relay Therapeutics' net margin of 0.00%. Halozyme Therapeutics' return on equity of 751.81% beat Relay Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	26.93%	751.81%	23.84%
Relay Therapeutics	N/A	-40.25%	-36.82%

Halozyme Therapeutics has higher revenue and earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	$1.40B	8.30	$316.89M	$3.93	25.87
Relay Therapeutics	$10.35M	421.00	-$276.48M	-$1.51	N/A

In the previous week, Halozyme Therapeutics had 15 more articles in the media than Relay Therapeutics. MarketBeat recorded 34 mentions for Halozyme Therapeutics and 19 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 0.74 beat Halozyme Therapeutics' score of 0.40 indicating that Relay Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Halozyme Therapeutics	7 Very Positive mention(s)	6 Positive mention(s)	14 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Relay Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

97.8% of Halozyme Therapeutics shares are held by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are held by institutional investors. 2.5% of Halozyme Therapeutics shares are held by company insiders. Comparatively, 5.0% of Relay Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Halozyme Therapeutics has a beta of 0.92, indicating that its stock price is 8% less volatile than the broader market. Comparatively, Relay Therapeutics has a beta of 1.74, indicating that its stock price is 74% more volatile than the broader market.

Halozyme Therapeutics currently has a consensus price target of $108.18, indicating a potential upside of 6.39%. Relay Therapeutics has a consensus price target of $27.00, indicating a potential upside of 36.92%. Given Relay Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Relay Therapeutics is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	1 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.62
Relay Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

Summary

Halozyme Therapeutics beats Relay Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Relay Therapeutics compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and Relay Therapeutics (NASDAQ:RLAY) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, valuation, earnings, dividends, analyst recommendations and risk.

Relay Therapeutics has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -59.84%. BridgeBio Pharma's return on equity of 0.00% beat Relay Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-59.84%	N/A	-39.81%
Relay Therapeutics	N/A	-40.25%	-36.82%

Relay Therapeutics has lower revenue, but higher earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$945.54M	16.39	-$724.93M	-$3.04	N/A
Relay Therapeutics	$10.35M	421.00	-$276.48M	-$1.51	N/A

In the previous week, Relay Therapeutics had 10 more articles in the media than BridgeBio Pharma. MarketBeat recorded 19 mentions for Relay Therapeutics and 9 mentions for BridgeBio Pharma. BridgeBio Pharma's average media sentiment score of 0.87 beat Relay Therapeutics' score of 0.74 indicating that BridgeBio Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Relay Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.8% of BridgeBio Pharma shares are owned by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are owned by institutional investors. 14.2% of BridgeBio Pharma shares are owned by insiders. Comparatively, 5.0% of Relay Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

BridgeBio Pharma has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market. Comparatively, Relay Therapeutics has a beta of 1.74, indicating that its stock price is 74% more volatile than the broader market.

BridgeBio Pharma currently has a consensus target price of $104.26, suggesting a potential upside of 31.08%. Relay Therapeutics has a consensus target price of $27.00, suggesting a potential upside of 36.92%. Given Relay Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Relay Therapeutics is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	19 Buy rating(s)	0 Strong Buy rating(s)	2.82
Relay Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

Summary

Relay Therapeutics beats BridgeBio Pharma on 11 of the 17 factors compared between the two stocks.

How does Relay Therapeutics compare to Summit Therapeutics?

Relay Therapeutics (NASDAQ:RLAY) and Summit Therapeutics (NASDAQ:SMMT) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, media sentiment, earnings, risk, institutional ownership and valuation.

Relay Therapeutics has a beta of 1.74, indicating that its share price is 74% more volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.49, indicating that its share price is 249% less volatile than the broader market.

97.0% of Relay Therapeutics shares are held by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are held by institutional investors. 5.0% of Relay Therapeutics shares are held by insiders. Comparatively, 81.8% of Summit Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Relay Therapeutics' return on equity of -40.25% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relay Therapeutics	N/A	-40.25%	-36.82%
Summit Therapeutics	N/A	-138.82%	-117.11%

Relay Therapeutics has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relay Therapeutics	$10.35M	421.00	-$276.48M	-$1.51	N/A
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.07	N/A

In the previous week, Relay Therapeutics had 2 more articles in the media than Summit Therapeutics. MarketBeat recorded 19 mentions for Relay Therapeutics and 17 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 0.94 beat Relay Therapeutics' score of 0.74 indicating that Summit Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relay Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Summit Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Relay Therapeutics currently has a consensus price target of $27.00, indicating a potential upside of 36.92%. Summit Therapeutics has a consensus price target of $28.61, indicating a potential upside of 71.92%. Given Summit Therapeutics' higher possible upside, analysts plainly believe Summit Therapeutics is more favorable than Relay Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relay Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
Summit Therapeutics	1 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.58

Summary

Relay Therapeutics beats Summit Therapeutics on 9 of the 13 factors compared between the two stocks.

Get Relay Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RLAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RLAY vs. The Competition

Export

Metric	Relay Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.41B	$4.15B	$7.90B	$12.02B
Dividend Yield	N/A	3.63%	2.45%	4.45%
P/E Ratio	-13.06	26.51	34.16	29.71
Price / Sales	421.00	16.34	8.65	5.75
Price / Cash	N/A	26.63	22.08	22.50
Price / Book	5.32	4.22	4.52	3.80
Net Income	-$276.48M	-$22.76M	$3.50B	$390.04M
7 Day Performance	16.00%	3.89%	2.53%	3.40%
1 Month Performance	9.68%	-5.18%	-3.21%	-5.35%
1 Year Performance	219.61%	-0.70%	1.01%	-5.92%

Relay Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RLAY Relay Therapeutics	3.0413 of 5 stars	$19.72 -1.1%	$27.00 +36.9%	+213.5%	$4.41B	$10.35M	N/A	218	Trending News Analyst Revision
EXEL Exelixis	2.378 of 5 stars	$70.13 +1.1%	$56.79 -19.0%	+64.5%	$17.19B	$2.50B	21.00	1,077	Analyst Upgrade High Trading Volume
ASND Ascendis Pharma A/S	4.3852 of 5 stars	$248.98 -0.9%	$305.95 +22.9%	+28.9%	$15.57B	$814.57M	19.32	1,189
HALO Halozyme Therapeutics	4.2389 of 5 stars	$128.95 -1.5%	$99.55 -22.8%	+45.0%	$14.76B	$1.40B	26.38	423	Earnings Report Analyst Upgrade
BBIO BridgeBio Pharma	3.5676 of 5 stars	$75.00 +0.1%	$104.26 +39.0%	+19.5%	$13.84B	$502.08M	N/A	839	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RLAY) was last updated on 11/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Relay Therapeutics (RLAY) Competitors

RLAY vs. EXEL, ASND, HALO, BBIO, and SMMT

How does Relay Therapeutics compare to Exelixis?

Summary

How does Relay Therapeutics compare to Ascendis Pharma A/S?

Summary

How does Relay Therapeutics compare to Halozyme Therapeutics?

Summary

How does Relay Therapeutics compare to BridgeBio Pharma?

Summary

How does Relay Therapeutics compare to Summit Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RLAY vs. The Competition

Relay Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Relay Therapeutics (RLAY) Competitors

RLAY vs. EXEL, ASND, HALO, BBIO, and SMMT

How does Relay Therapeutics compare to Exelixis?

Is EXEL or RLAY more profitable?

Which has better valuation and earnings, EXEL or RLAY?

Do institutionals & insiders have more ownership in EXEL or RLAY?

Does the media favor EXEL or RLAY?

Do analysts prefer EXEL or RLAY?

Which has more risk & volatility, EXEL or RLAY?

Summary

How does Relay Therapeutics compare to Ascendis Pharma A/S?

Is ASND or RLAY more profitable?

Do analysts rate ASND or RLAY?

Do institutionals and insiders believe in ASND or RLAY?

Does the media favor ASND or RLAY?

Which has better earnings and valuation, ASND or RLAY?

Which has more volatility and risk, ASND or RLAY?

Summary

How does Relay Therapeutics compare to Halozyme Therapeutics?

Is HALO or RLAY more profitable?

Which has preferable earnings and valuation, HALO or RLAY?

Does the media refer more to HALO or RLAY?

Do insiders and institutionals have more ownership in HALO or RLAY?

Which has more risk and volatility, HALO or RLAY?

Do analysts prefer HALO or RLAY?

Summary

How does Relay Therapeutics compare to BridgeBio Pharma?

Is BBIO or RLAY more profitable?

Which has stronger earnings & valuation, BBIO or RLAY?

Does the media refer more to BBIO or RLAY?

Do institutionals & insiders hold more shares of BBIO or RLAY?

Which has more volatility and risk, BBIO or RLAY?

Do analysts prefer BBIO or RLAY?

Summary

How does Relay Therapeutics compare to Summit Therapeutics?

Which has more volatility & risk, RLAY or SMMT?

Do institutionals and insiders have more ownership in RLAY or SMMT?

Is RLAY or SMMT more profitable?

Which has better earnings & valuation, RLAY or SMMT?

Does the media refer more to RLAY or SMMT?

Do analysts prefer RLAY or SMMT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RLAY vs. The Competition

Relay Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools